OTC · KLYG
Healthcare · Medical - Devices
$0.14
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 7:49 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 10 trading sessions · Daily adjusted prices
KLYG closed at $0.14 after 10 trading sessions, down 5.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $0.14 | $0.14 | $0.135 | $0.135 | 5K |
| Aug 12, 2026 | $0.14 | $0.148 | $0.14 | $0.14 | 26.75K |
| Aug 11, 2026 | $0.135 | $0.135 | $0.135 | $0.135 | 11.45K |
| Aug 6, 2026 | $0.1312 | $0.1312 | $0.1312 | $0.1312 | 500 |
| Aug 5, 2026 | $0.1312 | $0.1312 | $0.1312 | $0.1312 | 1K |
| Aug 3, 2026 | $0.125 | $0.125 | $0.125 | $0.125 | 12K |
| Jul 31, 2026 | $0.13 | $0.13 | $0.13 | $0.13 | 10.8K |
| Jul 28, 2026 | $0.127 | $0.127 | $0.126 | $0.126 | 1.5K |
| Jul 24, 2026 | $0.15 | $0.15 | $0.15 | $0.15 | 21.7K |
| Jul 20, 2026 | $0.1431 | $0.1431 | $0.1431 | $0.1431 | 8.6K |
The latest Smart Investors Daily articles mentioning KLYG.
KLYG research
Company profile and research snapshot.
KELYNIAM GLOBAL INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · May 11, 2026
Kelyniam Global (OTC: KLYG), a leader in custom cranial implants, today reported its financial results for the first quarter ended March 31, 2026. The company delivered excellent performance, with strong revenue growth and clear improvement in profitability.
GlobeNewswire Inc. · Nov 13, 2025
Kelyniam Global has obtained an exclusive two-year U.S. license from Evonik Industries to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material for cranial and craniofacial implants, expanding its regenerative medicine portfolio.
Yahoo · Nov 13, 2025
CANTON, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today announced it has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material, for cranial, craniofacial, and maxillofacial implants. This agreement grants Kelyniam two years of exclusivity with the option for renewal upon mutual agreement. The license enhances Kelyniam's regenerati
Benzinga · Nov 10, 2025
Kelyniam Global reported Q3 2025 financial results with decreased revenue and an operating loss, but remains optimistic about growth in the cranial implant sector through new product clearances and distributor expansion.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KLYG.
No results
No recent SID articles mention KLYG.
